SCHEMBL1625563

SCHEMBL1625563

CCc1nc2cc(-c3ccncc3)ccc2n1-c1ccc(CCN(C(=O)O)S(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.44
NTRK1 P04629 1/20 0.39
NTRK2 Q16620 1/20 0.39
PTGES O14684 1/20 0.37
ALOX5 P09917 1/20 0.37
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
GAA P10253 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
RECQL P46063 2/20 0.35
PDE10A Q9Y233 2/20 0.35
TP53 P04637 2/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
MTOR P42345 1/20 0.35
PIK3CG P48736 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1626033 0.93 PTGER4 (0.45) PTGER4NTRK1NTRK2PTGESALOX5
SCHEMBL1625526 0.91 PTGER4 (0.43) PTGER4NTRK1NTRK2PTGESALOX5
SCHEMBL1625825 0.91 PTGER4 (0.42) PTGER4NTRK1NTRK2PTGESALOX5
SCHEMBL1625814 0.87 PTGER4 (0.42) PTGER4NTRK1NTRK2SIRT2SIRT1
SCHEMBL1627922 0.87 PTGER4 (0.42) PTGER4NTRK1NTRK2ALDH1A1PKM
SCHEMBL1625211 0.86 PTGER4 (0.44) PTGER4NTRK1NTRK2ALDH1A1PKM
SCHEMBL1624296 0.86 PTGER4 (0.44) PTGER4NTRK1NTRK2ALDH1A1PKM
SCHEMBL1625541 0.85 PTGER4 (0.43) PTGER4NTRK1NTRK2ALDH1A1GAA
SCHEMBL1624692 0.84 NTRK1 (0.55) PTGER4NTRK1NTRK2MEN1KMT2A
SCHEMBL1624322 0.84 PTGER4 (0.43) PTGER4NTRK1NTRK2ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928119-B2 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PFIZER INC. (US) 2011-04-19 US disclosed
US-20070066618-A1 Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases PFIZER INC. 2007-03-22 US disclosed
US-7148234-B2 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PFIZER INC. (US) 2006-12-12 US disclosed
US-7141580-B2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PFIZER INC. (US) 2006-11-28 US disclosed
US-20040181059-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2004-09-16 US disclosed
US-6710054-B2 CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS PFIZER INC 2004-03-23 US disclosed
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases SHIMOJO MASATO 2003-12-25 US disclosed
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PFIZER PHARMACEUTICALS INC. (JP) 2002-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066618-A1 Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases PTGER4, PTGER1, IL6 PTGER4 1/4885NTRK1 2177/4885NTRK2 1928/4885
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PTGER4, PTGER1, IL6 PTGER4 1/4885NTRK1 2177/4885NTRK2 1928/4885
US-20040181059-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, OPRM1 PTGER4 55/4885NTRK1 3530/4885NTRK2 3668/4885
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PTGER4, PTGER1, PTGER2 PTGER4 1/4885NTRK1 1252/4885NTRK2 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.